Sodium phosphate tablets and acute phosphate nephropathy.
Mackey
Ann Corken
AC
Office of Surveillance and Epidemiology, Food and Drug Administration, Building 22, Room 3472, 10903 New Hampshire Avenue, Silver Spring, Maryland 20993, USA. ann.mackey@fda.hhs.gov
Green
Lanh
L
Amand
Keith St
KS
Avigan
Mark
M
D000208:Acute Disease; D000328:Adult; D000368:Aged; D002400:Cathartics / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000009:adverse effects / Q000378:metabolism*; D013607:Tablets
D002400:Cathartics; D010710:Phosphates; D013607:Tablets; C018279:sodium phosphate